Comparing 22 and 19G needles with EUS-FNB sampling for Cancer Gene Panel Test
Phase 2
Recruiting
- Conditions
- Pancreatic mass
- Registration Number
- JPRN-jRCT1062210071
- Lead Sponsor
- Hironari Kato
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 44
Inclusion Criteria
Patients with solid pancreatic mass planned for Cancer Gene Panel Testing using EUS-FNB samples
Exclusion Criteria
Performance status 3-4
Bleeding tendency or platelet count less than 50000/mm2
Taking two or more anti-thrombotic drugs
Difficult to perform EUS-FNB with safe due to interval vessels
Pregnant
Patients who could not obtain suitable informed consent
Patients judged by the reseach doctors as inappropriate subjects
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Collection rate of adequate tissue sampling for Cancer Gene Panel Test
- Secondary Outcome Measures
Name Time Method Tumor cell ratio <br>Tissue section surface area<br>Estimated amount of nucleic acid<br>Core tissue length<br>Histology score<br>Technical success<br>Adverse event<br>Success rate of Cancer Gene Panel Test<br>When there was a poorly enhanced area in tumor with CE-EUS, the above pathological evaluation will be performed using tissue samples obtained from poorly enhanced area